A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease.
- DOI
- 10.1016/j.kint.2026.05.018
- Published
- 2026-06-19
- Container
- Kidney Int
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.kint.2026.05.018,
title = {A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease.},
author = {Joly D and Ursino M and Bienaimé F and El Karoui K and Karras A and Thervet E and Boffa JJ and Galichon P and Luque Y and Michel PA and Cartery C and Vrtovsnik F and Daugas E and Peraldi MN and Colas S and Semeraro M and Treluyer JM and Meyzer C and Hummel A and Fouchard M and Nguyen-Khoa T and Knebelmann B and Alberti C.},
year = {2026},
journal = {Kidney Int},
doi = {10.1016/j.kint.2026.05.018},
url = {https://doi.org/10.1016/j.kint.2026.05.018}
}RIS
TY - JOUR TI - A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease. AU - Joly D AU - Ursino M AU - Bienaimé F AU - El Karoui K AU - Karras A AU - Thervet E AU - Boffa JJ AU - Galichon P AU - Luque Y AU - Michel PA AU - Cartery C AU - Vrtovsnik F AU - Daugas E AU - Peraldi MN AU - Colas S AU - Semeraro M AU - Treluyer JM AU - Meyzer C AU - Hummel A AU - Fouchard M AU - Nguyen-Khoa T AU - Knebelmann B AU - Alberti C. PY - 2026 JO - Kidney Int DO - 10.1016/j.kint.2026.05.018 UR - https://doi.org/10.1016/j.kint.2026.05.018 ER -
APA
D, J., M, U., F, B., K, E. K., A, K., E, T., JJ, B., P, G., Y, L., PA, M., C, C., F, V., E, D., MN, P., S, C., M, S., JM, T., C, M., A, H., M, F., T, N., B, K., & C., A. (2026). A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease.. Kidney Int. https://doi.org/10.1016/j.kint.2026.05.018
Source records
- europe-pmc · retrieved 2026-09-27T14:16:01.396Z